Dexcom, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Dexcom, Inc. Investors Of Deadline In Securities Fraud Class Action Lawsuit

2025-12-17 12:17:37

(MENAFN- GlobeNewsWire - Nasdaq) RADNOR, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM ) on behalf of those who purchased or otherwise acquired DexCom securities between January 8, 2024, and September 17, 2025, inclusive (the“Class Period”). The lead plaintiff deadline is December 26, 2025.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered DexCom losses, contact KTMC at:

You can also contact attorney href="" rel="nofollow" target="_blank" title=""> Jonathan Naji, Esq. by calling (484) 270-1453 or by email at ....

DEFENDANTS' ALLEGED MISCONDUCT:
The complaints allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 continuous glucose monitoring systems that were unauthorized by the FDA; (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) DexCom's purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (4) DexCom downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Please CLICK HERE to view our video or copy and paste this link into your browser:

THE LEAD PLAINTIFF PROCESS:
DexCom investors may, no later than December 26, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages DexCom investors who have suffered significant losses to contact the firm directly to acquire more information.

SIGN UP FOR THE CASE AT:
Text>
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. For more information about Kessler Topaz Meltzer & Check, LLP, please visit .

CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
href="" rel="nofollow" target="_blank" title="...">...

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

MENAFN17122025004107003653ID1110489102

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.